Pulses are our e-newsletters that look at recent trends and promising directions across life sciences. Add your name to our mail list to receive future updates.
Past Issues
CNS Pulse | July 2024
Outlook on Rare Neurodegenerative Diseases: ALS and SMA
Rare neurodegenerative diseases have benefited from an influx of novel therapies, but the remaining unmet needs and clinical development strategies vary by disease and continue to pose a challenge.
Oncology Pulse | May 2024
Flight to Safety or Breakthrough? Resurgence of ADCs and Radiopharmaceuticals
Antibody-drug conjugates (ADCs) and radiopharmaceuticals have re-emerged as modalities of high interest in oncology licensing and acquisition – will they be the next wave of breakthroughs or represent a flight to safety in light of the challenges of finding the next hot target and the IRA?
Oncology Pulse | Jan. 2024
New Oncology Agents – A Look Back and the Year Ahead
Follow-on targeted therapies and T-cell engagers for liquid tumors accounted for most of the new oncology agents last year; 18 drugs and 9 MOAs are already filed for this year, with cell therapies and a T-cell engager for solid tumors and a new ADC target on the list of potential approvals.
Gene Therapy Pulse | Dec. 2023
Outlook on Gene Therapy
The cell and gene therapy space has seen significant growth in the last five years and continues to rapidly evolve. Realization of future potential faces key technical, clinical, and commerical challenges.
Oncology Pulse | Nov. 2023
Challengers to Auto CAR-T in Liquid Tumors, namely bispecific T-cell engagers and allogeneic CAR-T, are emerging.
For now, auto CAR-T is prioritized over bispecifics due to longer term data, but both approaches are seeking to push into earlier lines and allogeneic CAR-Ts are aiming to provide the efficacy of CAR-T with an off-the-shelf product.
Oncology Pulse | Sept. 2023
Overcoming checkpoint inhibitor (CPI) resistance has been a major area of investigation with few successes so far.
Segmenting PD-(L)1 rechallenge patients by type of resistance could be a path to success — and assumptions for efficacy post-CPI may need to be increased.
Oncology Pulse | May 2023
The inaugural issue categorizes FDA approvals for oncology therapies over the past five years and notes programs to watch in 2023.
Targeted therapies have accounted for the majority of new oncology drugs over the past five years, but a more diverse set of approaches are being approved; IRA and accelerated approval changes also portend changes.